masitinib mesylate

Details

Key Milestones²
Milestones title	Date
Call for patient/clinician input open	29-Sep-22
Call for patient/clinician input closed	18-Nov-22
Clarification: - Patient input submission received from ALS Action Canada and ALS Society of Canada
Submission received	28-Oct-22
Submission accepted	15-Nov-22
Clarification: - Submission was not accepted for review on 11 Nov 2022
Review initiated	16-Nov-22
Clarification: - Submission temporarily suspended
Draft CADTH review report(s) provided to sponsor for comment	-
Deadline for sponsors comments	-
CADTH review report(s) and responses to comments provided to sponsor	-
Expert committee meeting (initial)	-
Draft recommendation issued to sponsor	-
Draft recommendation posted for stakeholder feedback	-
End of feedback period	-

Last Updated : March 5, 2025

ravulizumab

Details

Key Milestones²
Milestones title	Date
Call for patient/clinician input open	26-Sep-22
Call for patient/clinician input closed	18-Nov-22
Clarification: - Patient input submission received from Muscular Dystrophy Canada
Submission received	25-Oct-22
Submission accepted	08-Nov-22
Review initiated	09-Nov-22
Draft Canada's Drug Agency review report(s) provided to sponsor for comment	03-Feb-23
Deadline for sponsors comments	14-Feb-23
Canada's Drug Agency review report(s) and responses to comments provided to sponsor	09-Mar-23
Expert committee meeting (initial)	22-Mar-23
Draft recommendation issued to sponsor	04-Apr-23
Draft recommendation posted for stakeholder feedback	13-Apr-23
End of feedback period	27-Apr-23
Clarification: - Reconsideration: major revisions requested by sponsor
Expert committee meeting	26-Jul-23
Final recommendation issued to sponsor and drug plans	08-Aug-23
Final recommendation posted	24-Aug-23
Deadline for sponsor to submit redaction requests on draft Canada's Drug Agency review report(s)	22-Aug-23
Canada's Drug Agency review report(s) posted	27-Oct-23

Last Updated : October 27, 2023

selumetinib

Details

Key Milestones²
Milestones title	Date
Call for patient/clinician input open	September 26, 2022
Call for patient/clinician input closed	November 18, 2022
Clarification: - Patient input submission received from Canadian Organization for Rare Disorders (CORD)and Tumour Foundation of BC
Submission received	October 28, 2022
Submission accepted	November 11, 2022
Review initiated	November 14, 2022
Draft Canada's Drug Agency review report(s) provided to sponsor for comment	February 03, 2023
Deadline for sponsors comments	February 14, 2023
Canada's Drug Agency review report(s) and responses to comments provided to sponsor	March 09, 2023
Expert committee meeting (initial)	March 22, 2023
Draft recommendation issued to sponsor	April 05, 2023
Draft recommendation posted for stakeholder feedback	April 13, 2023
End of feedback period	April 27, 2023
Final recommendation issued to sponsor and drug plans	May 10, 2023
Final recommendation posted	May 29, 2023
Deadline for sponsor to submit redaction requests on draft Canada's Drug Agency review report(s)	May 25, 2023
Canada's Drug Agency review report(s) posted	July 20, 2023

Last Updated : July 24, 2023

daprodustat

Details

Key Milestones²
Milestones title	Date
Call for patient/clinician input open	September 26, 2022
Call for patient/clinician input closed	November 18, 2022
Clarification: - Patient input submission received from The Kidney Foundation of Canada
Submission received	October 25, 2022
Submission accepted	November 08, 2022
Review initiated	November 09, 2022
Draft Canada's Drug Agency review report(s) provided to sponsor for comment	February 01, 2023
Deadline for sponsors comments	February 10, 2023
Canada's Drug Agency review report(s) and responses to comments provided to sponsor	March 09, 2023
Expert committee meeting (initial)	March 22, 2023
Clarification: - CDEC recommendation held pending receipt of NOC and evaluation of the finalized submission requirements. - Voluntarily withdrawn by the sponsor on 24 Jul 2023.

Last Updated : July 24, 2023

palovarotene

Details

Key Milestones²
Milestones title	Date
Call for patient/clinician input open	September 22, 2022
Call for patient/clinician input closed	November 11, 2022
Clarification: - Patient input submission received from The Canadian FOP Network (CFOPN) & The Canadian Organization for Rare Disorders (CORD)
Submission received	October 21, 2022
Submission accepted	November 04, 2022
Review initiated	November 07, 2022
Draft Canada's Drug Agency review report(s) provided to sponsor for comment	February 06, 2023
Deadline for sponsors comments	February 15, 2023
Canada's Drug Agency review report(s) and responses to comments provided to sponsor	March 09, 2023
Expert committee meeting (initial)	March 22, 2023
Draft recommendation issued to sponsor	April 05, 2023
Draft recommendation posted for stakeholder feedback	April 13, 2023
End of feedback period	April 27, 2023
Final recommendation issued to sponsor and drug plans	May 11, 2023
Final recommendation posted	May 30, 2023
Deadline for sponsor to submit redaction requests on draft Canada's Drug Agency review report(s)	May 26, 2023
Canada's Drug Agency review report(s) posted	August 01, 2023

Last Updated : August 1, 2023

upadacitinib

Details

Key Milestones²
Milestones title	Date
Call for patient/clinician input open	16-Sep-22
Call for patient/clinician input closed	11-Nov-22
Clarification: - Patient input submission received from the Canadian Arthritis Patient Alliance, Canadian Spondylitis Association, Arthritis Society, CreakyJoints Canada
Submission received	17-Oct-22
Submission accepted	31-Oct-22
Review initiated	01-Nov-22
Draft Canada's Drug Agency review report(s) provided to sponsor for comment	02-Feb-23
Deadline for sponsors comments	13-Feb-23
Canada's Drug Agency review report(s) and responses to comments provided to sponsor	09-Mar-23
Expert committee meeting (initial)	22-Mar-23
Draft recommendation issued to sponsor	03-Apr-23
Draft recommendation posted for stakeholder feedback	13-Apr-23
End of feedback period	27-Apr-23
Final recommendation issued to sponsor and drug plans	11-May-23
Final recommendation posted	30-May-23
Deadline for sponsor to submit redaction requests on draft Canada's Drug Agency review report(s)	26-May-23
Canada's Drug Agency review report(s) posted	28-Aug-23

Last Updated : August 28, 2023

vericiguat

Details

Key Milestones²
Milestones title	Date
Call for patient/clinician input open	15-Sep-22
Call for patient/clinician input closed	04-Nov-22
Clarification: - Patient input submission received from HeartLife Foundation and Heart function clinic Vancouver General Hospital, St Paul's Hospital
Submission received	14-Oct-22
Submission accepted	28-Oct-22
Review initiated	31-Oct-22
Draft Canada's Drug Agency review report(s) provided to sponsor for comment	19-Jan-23
Deadline for sponsors comments	31-Jan-23
Canada's Drug Agency review report(s) and responses to comments provided to sponsor	09-Mar-23
Expert committee meeting (initial)	22-Mar-23
Draft recommendation issued to sponsor	10-May-23
Draft recommendation posted for stakeholder feedback	18-May-23
End of feedback period	02-Jun-23
Final recommendation issued to sponsor and drug plans	14-Jun-23
Final recommendation posted	30-Jun-23
Deadline for sponsor to submit redaction requests on draft Canada's Drug Agency review report(s)	28-Jun-23
Canada's Drug Agency review report(s) posted	30-Aug-23

Last Updated : August 30, 2023

CADTH Pharmaceutical Reviews Update — Issue 31

Details

See Pharmaceutical Reviews Update ― Issue 31 for important news and information regarding the Canada's Drug Agency drug review programs. Highlights from this issue include:

Last Updated : September 1, 2022

deucravacitinib

Details

Key Milestones²
Milestones title	Date
Call for patient/clinician input open	29-Aug-22
Call for patient/clinician input closed	24-Oct-22
Clarification: - Patient input submission received from the Canadian Psoriasis Network (CPN) and Canadian Association of Psoriasis Patients (CAPP)
Submission received	27-Sep-22
Submission accepted	12-Oct-22
Review initiated	13-Oct-22
Draft Canada's Drug Agency review report(s) provided to sponsor for comment	03-Jan-23
Deadline for sponsors comments	12-Jan-23
Canada's Drug Agency review report(s) and responses to comments provided to sponsor	09-Feb-23
Expert committee meeting (initial)	22-Feb-23
Draft recommendation issued to sponsor	07-Mar-23
Draft recommendation posted for stakeholder feedback	16-Mar-23
End of feedback period	31-Mar-23
Clarification: - Reconsideration: major revisions requested by sponsor
Expert committee meeting	26-Jul-23
Final recommendation issued to sponsor and drug plans
Final recommendation posted	24-Aug-23
Deadline for sponsor to submit redaction requests on draft Canada's Drug Agency review report(s)	22-Aug-23
Canada's Drug Agency review report(s) posted	25-Oct-23

Last Updated : October 25, 2023

ciltacabtagene autoleucel

Details

Key Milestones²
Milestones title	Date
Call for patient/clinician input open	25-Aug-22
Call for patient/clinician input closed	17-Oct-22
Clarification: - Patient input submission received from Myeloma Canada
Submission received	23-Sep-22
Submission accepted	07-Oct-22
Review initiated	11-Oct-22
Draft Canada's Drug Agency review report(s) provided to sponsor for comment	22-Dec-22
Deadline for sponsors comments	10-Jan-23
Canada's Drug Agency review report(s) and responses to comments provided to sponsor	24-Feb-23
Expert committee meeting (initial)	08-Mar-23
Draft recommendation issued to sponsor	21-Mar-23
Draft recommendation posted for stakeholder feedback	30-Mar-23
End of feedback period	14-Apr-23
Final recommendation issued to sponsor and drug plans	01-May-23
Final recommendation posted	17-May-23
Deadline for sponsor to submit redaction requests on draft Canada's Drug Agency review report(s)	15-May-23
Canada's Drug Agency review report(s) posted	02-Aug-23

Last Updated : August 2, 2023